Clinical Trial Update: The Effect of MK0859 on Lipoprotein Metabolism in Patients With Dyslipidemia (0859-026 AM3) [Phase 1]

View source ↗

Summary

Phase 1 study evaluating MK0859 for its effect on lipoprotein metabolism in patients with dyslipidemia; the trial has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dyslipidemia

Drugs mentioned

• MK0859

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Dyslipidemia | Phase 1 | Status: COMPLETED